CCG-203971
SIGMA/SML1422 - ≥98% (HPLC)
Synonym: N-
CAS Number: 1443437-74-8
Empirical Formula (Hill Notation): C23H21ClN2O3
Molecular Weight: 408.88
MDL Number: MFCD28166491
Linear Formula: C23H21ClN2O3
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to beige |
| form | powder |
| InChI | 1S/C23H21ClN2O3/c24-19-8- |
| InChI key | HERLZBNILRVHQN-UHFFFAOYSA |
| Quality Level | 100 ![]() |
| SMILES string | ClC(C=C1)=CC=C1NC(C(C2)CC |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | CCG-203971 is an inhibitor of the Rho/MKL1/SRF transcriptional pathway, which has been shown to play a role in metastasis of melanoma and breast cancer and clinically associated with castration-resistant prostate cancer. CCG-203971 is a second-generation analog of CCG-1423 (SML0987) with an IC50 of 4.2 μM vs 1 μM for CCG-1423, but less cytotoxicity. In mouse studies, CCG-203971 inhibited invasion of PC-3 prostate cancer cells and was well tolerated up to doses of 100 mg/kg IP over 5 days. The Rho/MRTF/SRF pathway has also been shown to be involved in multiple types of solid organ fibrosis. CCG-203971 repressed both matrix-stiffness and TGF-β-mediated fibrogenesis in human colonic myofibroblasts and showed antifibrotic activity in a murine model of skin injury and in pulmonary fibrosis lung fibroblasts. |
| Biochem/physiol Actions: | CCG-203971 is an inhibitor of the Rho/MKL1/SRF transcriptional pathway. |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol | GHS07 |
| Signal word | Warning |
| Hazard statements | H302 |
| Precautionary statements | P301 + P312 + P330 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |


